Form 8-K - Current report:
SEC Accession No. 0001683168-25-003575
Filing Date
2025-05-15
Accepted
2025-05-14 18:52:01
Documents
17
Period of Report
2025-05-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cns_8k.htm   iXBRL 8-K 39010
2 PLACEMENT AGENT AGREEMENT DATED MAY 13, 2025 cns_ex0101.htm EX-1.1 50326
3 FORM OF SERIES F COMMON WARRANT cns_ex0401.htm EX-4.1 98425
4 FORM OF PRE-FUNDED WARRANT cns_ex0402.htm EX-4.2 93237
5 FORM OF SECURITIES PURCHASE AGREEMENT cns_ex1001.htm EX-10.1 239809
  Complete submission text file 0001683168-25-003575.txt   820737

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnsp-20250513.xsd EX-101.SCH 3017
7 XBRL LABEL FILE cnsp-20250513_lab.xml EX-101.LAB 34239
8 XBRL PRESENTATION FILE cnsp-20250513_pre.xml EX-101.PRE 22360
19 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3802
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 25947707
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)